Investors look for Pfizer, Allergan, Mylan, Baxalta and others to address big questions at JP Morgan conference

Eric Palmer

There are big facing some of pharma's key players this year, like whether the and deal will get done and why thinks that is its best route. Or what intends to do since it spurned a buyout from Teva but failed to close on Perrigo. At least some of those can be expected to be answered next week when nearly all of pharma, large and small, convene in San Francisco for the JP Healthcare .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS